首页> 外文期刊>European review for medical and pharmacological sciences. >LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway
【24h】

LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway

机译:LncRNA HULC通过上调鞘氨醇激酶1(SPHK1)及其下游PI3K / Akt途径促进非小细胞肺癌细胞增殖并抑制细胞凋亡

获取原文
           

摘要

OBJECTIVE: LncRNA HULC has been proved to have important functions in the pathogenesis of several types of cancers. While its involvement in non-small cell lung cancer (NSCLC), which is one of the most common malignancies, still hasn’t been reported to date. Therefore, we aimed to investigate the role of HULC in NSCLC and to explore the possible mechanisms. PATIENTS AND METHODS: Tumor tissues and adjacent healthy tissues were collected from NSCLC patients, and blood samples were collected from both NSCLC patients and healthy controls. Expression of HULU in those tissues was detected by qRT-PCR. All patients were followed up for 5 years. Diagnostic and prognostic values of serum HULU for NSCLC were investigated by ROC curve analysis and survival curve analysis, respectively. HULC overexpression NSCLC cell lines were established and its effects on cell proliferation as well as apoptosis were investigated by CCK-8 assay and MTT assay, respectively. Effects of HULC overexpression on sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway were investigated by Western blot. RESULTS: HULC expression level was increased in tumor tissues compared with adjacent healthy tissues in most patients. Serum level of HULC was higher in cancer patients than that in healthy control. Serum level of HULC was increased with the increased stage of primary tumor (T stage). Serum HULC can be used to accurately predict NSCLC and its prognosis. HULC overexpression promoted tumor cell proliferation, but inhibited cell apoptosis. HULC overexpression also increased expression level of SPHK1 and phosphorylation level of Akt in NSCLC cell, but showed on significant effects on Akt expression. Treatment with SPHK1 inhibitor and Akt reduced the effects of HULC overexpression on proliferation and apoptosis of NSCLC cells. But the treatment showed no significant effects on HULC expression. SPHK1 inhibitor treatment inhibited phosphorylation of Akt, while Akt inhibitor treatment showed no significant effects on SPHK1 expression. CONCLUSIONS: LncRNA HULC overexpression can promote NSCLC cell proliferation and inhibit cell apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and further induce the activation of its downstream PI3K/Akt pathway.
机译:目的:LncRNA HULC已被证明在多种类型癌症的发病机制中具有重要作用。尽管它参与了非小细胞肺癌(NSCLC),这是最常见的恶性肿瘤之一,但至今尚未见报道。因此,我们旨在调查HULC在NSCLC中的作用并探讨可能的机制。病人和方法:从NSCLC患者中收集肿瘤组织和邻近的健康组织,并从NSCLC患者和健康对照者中收集血液样品。通过qRT-PCR检测HULU在那些组织中的表达。所有患者均获随访5年。通过ROC曲线分析和生存曲线分析分别研究了血清HULU对NSCLC的诊断和预后价值。建立了HULC过表达的NSCLC细胞系,并通过CCK-8法和MTT法研究了其对细胞增殖和凋亡的影响。通过蛋白质印迹研究了HULC过表达对鞘氨醇激酶1(SPHK1)及其下游PI3K / Akt通路的影响。结果:与大多数健康组织相比,肿瘤组织中HULC的表达水平升高。癌症患者的血清HULC水平高于健康对照组。 HULC的血清水平随着原发肿瘤阶段(T阶段)的增加而增加。血清HULC可用于准确预测NSCLC及其预后。 HULC的过表达促进肿瘤细胞增殖,但抑制细胞凋亡。 HULC的过表达还增加了NSCLC细胞中SPHK1的表达水平和Akt的磷酸化水平,但是显示出对Akt表达的显着影响。 SPHK1抑制剂和Akt的治疗降低了HULC过表达对NSCLC细胞增殖和凋亡的影响。但是该处理对HULC表达没有显着影响。 SPHK1抑制剂处理可抑制Akt的磷酸化,而Akt抑制剂处理对SPHK1的表达无明显影响。结论:LncRNA HULC过表达可通过上调鞘氨醇激酶1(SPHK1)促进NSCLC细胞增殖并抑制细胞凋亡,并进一步诱导其下游PI3K / Akt途径的激活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号